Bli medlem
Bli medlem

Du är här


Nordic Nanovector: Nordic Nanovector - Private placement successfully completed

Date: 07.12.2016        Press Release no: 66/2016

Not for release, publication or distribution, directly or indirectly,
in the United States of America, Canada, Japan or Australia

Oslo, Norway, 7 December 2016

Reference is made to the stock exchange release from Nordic Nanovector
ASA (OSE: NANO) ("Nordic Nanovector" or the "Company"), published 6
December 2016 regarding the contemplated undocumented private
placement of new shares in the Company.

The Company announces today that it has raised NOK 498,663,816 in
gross proceeds through a private placement of 4,374,244 new shares
(the "Private Placement"). The Private Placement was completed at a
subscription price of NOK 114 per share, which was determined through
an accelerated book-building process.

DNB Markets, Jefferies International Limited and ABG Sundal Collier
acted as joint bookrunners (the "Joint Bookrunners") in connection
with the Private Placement, which took place after close of trading
yesterday. The Private Placement, which was oversubscribed, attracted
strong interest from both existing shareholders and new institutional

Nordic Nanovector intends to use the net proceeds of the Private

· To fund a Phase 2 combination study of Betalutin® and Rituximab CD20
· To fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody (anti-CD37 ARC)
· Develop new proprietary antibody production technology
· Accelerate pipeline of pre-clinical assets to clinical trials
· Prepare for commercial launch of Betalutin®
· General corporate purposes

The Private Placement and the issuance of the new shares was resolved
by the Company's Board of Directors (the "Board") at a board meeting
held on 6 December 2016, based on the authorisation granted to the
Board at the Company's annual general meeting on 19 May 2016.
Notification of allotment in the Private Placement and payment
instructions will be sent to the applicants today through a
notification from the Joint Bookrunners. The new shares will be
settled delivery versus payment on 9 December 2016 (regular T+2
settlement), by delivery of existing and unencumbered shares in the
Company that are already listed on the Oslo Stock Exchange pursuant
to a share lending agreement between DNB Markets (on behalf of the
Joint Bookrunners) and HealthCap VI L.P. The new shares delivered to
the subscribers will thus be tradable from allocation.

Following registration of the new share capital pertaining to the
Private Placement in the Norwegian Register of Business Enterprises,
expected to take place on or about 13 December 2016, the Company will
have an issued share capital of NOK 9,794,924, divided into
48,974,618 shares, each with a par value of NOK 0.20.

The Board has assessed the Private Placement in light of the equal
treatment requirement, balanced the considerations that speak for and
against carrying out the Private Placement and concluded that the
waiver of the preferential rights inherent in a private placement was
considered necessary in the interest of time and successful
completion in the common interest of the Company and its

The Company's latest investor presentation is available at:

For further information, please contact:

For Nordic Nanovector

IR enquiries:

Luigi Costa, Chief Executive Officer

Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76


Media enquiries:

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 282 2948/+44 207 282 2949


About Nordic Nanovector:

Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and
oncology. The Company's lead clinical-stage product opportunity is
Betalutin®, the first in a new class of
Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and
complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over
$12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody, lilotomab,
conjugated to a low intensity radionuclide (lutetium-177). The
preliminary data has shown promising efficacy and safety profile in
an ongoing Phase 1/2 study in a difficult-to-treat NHL patient
population. The Company is aiming at developing Betalutin® for the
treatment of major types of NHL with first regulatory submission
anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets,
while exploring potential distribution agreements in selected
geographies. The Company is committed to developing its pipeline of
innovative targeted immunoconjugate therapies for multiple selected
cancer indications.

Further information about the Company can be found at

This information is subject to the disclose requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Important Notices

This document is not an offer to sell or a solicitation of offers to
purchase or subscribe for shares. Copies of this document may not be
sent to jurisdictions, or distributed in or sent from jurisdictions,
in which this is barred or prohibited by law. The information
contained herein shall not constitute an offer to sell or the
solicitation of an offer to buy, in any jurisdiction in which such
offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities
laws of any jurisdiction.

This document is not for publication or distribution in the United
States of America, Canada, Australia or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any
securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should
not be distributed or otherwise transmitted into the United States of
America or to U.S. persons (as defined in the U.S. Securities Act of
1933, as amended (the "Securities Act")) or to publications with a
general circulation in the United States of America. This document is
not an offer for sale of securities in the United States. The
securities referred to herein have not been and will not be
registered under the Securities Act, or the laws of any state, and
may not be offered or sold in the United States of America absent
registration under or an exemption from registration under Securities
Act. Nordic Nanovector does not intend to register any part of the
offering in the United States, There will be no public offering of
the securities in the United States of America. Any public offering
in the United States would be made by means of a prospectus
containing detailed information about the company and management, as
well as financial statements.

The information contained herein does not constitute an offer of
securities to the public in the United Kingdom. No prospectus
offering securities to the public will be published in the United
Kingdom. This document is only being distributed to and is only
directed at (i) persons who are outside the United Kingdom or (ii) to
investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order
2005 (the "Order") or (iii) high net worth entities, and other
persons to whom it may lawfully be communicated, falling within
article 49(2)(a) to (d) of the Order (all such persons together being
referred to as "relevant persons"). The securities are only available
to, and any invitation, offer or agreement to subscribe, purchase or
otherwise acquire such securities will be engaged in only with,
relevant persons. Any person who is not a relevant person should not
act or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made
pursuant to this communication in any member state of the European
Economic Area (each an "EEA Member State") that has implemented
Directive 2003/71/EC (together with the 2010 PD Amending Directive
2010/73/EU, including any applicable implementing measures in any
Member State, the "Prospectus Directive") is only addressed to
qualified investors in that Member State within the meaning of the
Prospectus Directive.

Investing in securities involves certain risks. You should read the
Risk Factors contained in the prospectus dated 10 March 2015
(available at,
but they should be read in light of any new or additional information
contained in any further publicly available information since the
date of the prospectus.

This publication may contain specific forward-looking statements, e.g.
statements including terms like "believe", "assume", "expect",
"forecast", "project", "may", "could", "might", "will" or similar
expressions. Such forward-looking statements are subject to known and
unknown risks, uncertainties and other factors which may result in a
substantial divergence between the actual results, financial
situation, development or performance of Nordic Nanovector and those
explicitly or implicitly presumed in these statements. Against the
background of these uncertainties, readers should not rely on
forward-looking statements. Nordic Nanovector assumes no
responsibility to update forward-looking statements or to adapt them
to future events or developments.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.